Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,525 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06191250 | --SuPERIOR Trial-- | terminated | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | terminated | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | terminated | Phase 2 | 648 | Spectrum Pharmaceuticals, IncINDUSTRY | 8 | Jun 12, 2026 | clinicaltrials |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | terminated | Phase 2 | 33 | NeoImmuneTechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab | terminated | Phase 1 / Phase 2 | 6 | University of NebraskaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | terminated | Phase 2 | 1 | University of California, DavisOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05316467 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | terminated | Phase 2 / Phase 3 | 8 | Xiaojun ChenOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | terminated | Phase 2 | 9 | University of OklahomaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03331601 | Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients | terminated | Phase 2 | 7 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)(LUNAR-4) | terminated | Phase 2 | 31 | NovoCure GmbHINDUSTRY | 7 | Jun 1, 2026 | clinicaltrials |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma(GCISAVE) | terminated | Phase 2 | 65 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03646461 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | terminated | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04169074 | Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial) | terminated | Phase 2 | 7 | University of ArizonaOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Corcept TherapeuticsINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | terminated | Phase 2 | 225 | Iovance Biotherapeutics, Inc.INDUSTRY | 7 | May 15, 2026 | clinicaltrials |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 15 | Thomas HopeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects | terminated | Phase 2 | 11 | University of California, DavisOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | May 14, 2026 | clinicaltrials |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)(Morpheus Lung) | terminated | Phase 1 / Phase 2 | 314 | Hoffmann-La RocheINDUSTRY | 7 | May 12, 2026 | clinicaltrials |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)(INTerpath-007) | terminated | Phase 2 / Phase 3 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 8, 2026 | clinicaltrials |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | terminated | Phase 2 | 8 | University of CincinnatiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | terminated | Phase 2 | 4 | University of WashingtonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | terminated | Phase 2 | 13 | Partner Therapeutics, Inc.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | terminated | Phase 1 / Phase 2 | 52 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | terminated | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.(DICE) | terminated | Phase 2 | 7 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer | terminated | Phase 2 | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer(PIPSeN) | terminated | Phase 2 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 29, 2026source: clinicaltrials